Home›Trial›NCT05138133
🔬NCT05138133Phase 3ACTIVE NOT RECRUITING

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Study Summary

The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis

Conditions
Lupus Nephritis
Interventions / Drugs
AnifrolumabPlacebo
View on ClinicalTrials.gov ↗
Sponsor
AZN
AstraZeneca
Oncology/Respiratory
F15/100
Study Details
Enrollment359 participants
Primary Completion—
Lead SponsorAstraZeneca
Data Retrieved2026-04-11 02:55:19.911072+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.